Sobre los efectos adversos en la vida real

Darío Scublinsky

doi:10.47196/rar.v27i1.596

Darío Scublinsky Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina

DOI: https://doi.org/10.47196/rar.v27i1.596

Palabras clave: editorial, reumatología

Resumen

En los tiempos en que la terapéutica farmacológica estaba en sus inicios, allá por fines del siglo XIX, se publica en The Lancet uno de los primeros reportes científicos de efectos adversos, que se trataba de las drogas anestésicas utilizadas en dicho momento. Algunos años después, la American Medical Association publica un artículo donde se denuncian los efectos mortales del jarabe de Winslow, “capaz de calmar a cualquier persona o animal”, que era ni más ni menos que una combinación de morfina y alcohol.

Biografía del autor/a

Darío Scublinsky, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina

Médico Reumatólogo, coordinador de la Unidad de Farmacovigilancia, primera cátedra de Farmacología, Facultad de Medicina

Citas

I. Commission on Anaesthetics. Lancet. 1893; i:629-638.

II. Christen AG1, Christen JA. Sozodont powder dentifrice and Mrs. Winslow's Soothing Syrup: dental nostrums. J Hist Dent. 2000 Nov; 48(3):99-105.

III. Von Oettingen WF, Jirouch EA. The pharmacology of ethylene glycol and some of its derivatives in relation to their chemical constitution and physical chemical properties. J Pharmacol Exp Ther July 1931; 42:355-372.

IV. Fallo de la Sala Tercera de la Cámara Federal de Apelaciones de La Plata, expediente N. 12.262/05.

V. P. 681. XLIII. Fallo de la Corte Suprema de la Nación carátula: "Parisi de Frezzini, Francisca c/ Laboratorios Huilén y otros s/daños y perjuicios." -20 de octubre de 2009.

VI. Takumi I, Hideki A, et al. Identification of a Primary Target of Thalidomide Teratogenicity. Science 12 Mar 2010; Vol. 327, 5971: 1345-1350.

VII. McBride WG. Thalidomide and congenital abnormalities. The Lancet Vol 278, 7216, 16 Dec 1961: 1358.

VIII. Lenz W. The history of thalidomide. The Thalidomide Victims Association of Canada. http:// www.thalidomide.ca/history-of-thalidomide/

IX. Inman WHW. Monitoring for Drug Safety. J B Lippincott Co & MTP Press Ltd, Lancaster, 1980.

X. Organización mundial de la Salud. http://apps.who. int/

XI. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British society for rheumatology biologics register (BSRBR). Ann Rheum Dis 2010; 69:522-528.

XII. Strangfield A, Hierse F, Rau R, Burmester GR, Krummel-Lorenz B, Demary W, et al. Risk of incidence or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010; 12:R5.

XIII. Strangfeld A, Herse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R, et al. Comparative effectiveness of tumour necrosis alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 2009; 68:1856-1862.

XIV. BIOBADASER. BIOBADASER: http://biobadaser.ser.es/biobadaser/eng/docs/report_260603.PDF

XV. Gomez-Reino JJ, Carmona L, Descalzo MA. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57:756-761.

XVI. L jung L, Rantapää-Dahlqvist S, Jacobsson LT, Askling J. Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. Ann Rheum Dis. 2016 Mar 16. pii: annrheumdis-2015-208995. doi: 10.1136/ annrheumdis-2015-208995. [Epub ahead of print].

XVII. Pappas DA1, Oh C, Plenge RM, Kremer JM, Greenberg JD. Association of rheumatoid arthritis risk alleles with response to anti-TNF biologics: results from the CORRONA registry and meta-analysis. Inflammation. 2013 Apr; 36(2):279-84.

XVIII. Yoshida K, Radner H, Mjaavatten MD, Greenberg JD, Kavanaugh A, et al. Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study. J Rheumatol. 2015 Dec; 42(12):2238-46.

XIX. Gerhold K, Richter A, Schneider M, Bergerhausen HJ, Demary W, Liebhaber A, et al. Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT. Rheumatology (Oxford). 2015 Oct; 54(10):1858-66.

XX. A jeganova S, Humphreys JH, Verheul MK, van Steenbergen HW, van Nies JA, Hafström I. Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts. Ann Rheum Dis. 2016 Jan 12. pii: annrheumdis-2015-208579. [Epub ahead of print].

XXI. de la Vega M, Casado G, Citera G, Soriano E, Venarotti H, et al. Primer reporte de efectos adversos de tratamientos biológicos en Argentina. Informe de Registro BIOBADASAR. Rev Arg Reumatol 2011; 22:40-54.

XXII. de la Vega M, da Silveira de Carvalho H, Ventura Ríos L, Goycochea Robles M, Casado G. The importance of rheumatology biologic registries in Latin America. Rheumatol Int 2013; 33:827-835.